Objective: To comprehensive evaluate the effect of inhaled corticosteroids (ICS) suspensions in children with acute asthma with nebulized fluticasone propionate (FP) as the core drug. Methods: Systematic review of relevant literature and economic analysis were conducted to comprehensively evaluate the effectiveness

safety

economy

suitability

accessibility and innovation. Results: (1) Effectiveness

FP significantly improved morning peak expiratory flow ( PEF ) compared with double-dose budesonide ( BUD) suspension

while double-dose BUD significantly reduced the absence of asthma attack at night. (2) Safety

there were no significant differences between FP and BUD suspension in children with acute asthma in the aspects of serum cortisol levels in the morning

urine cortisol levels at night

incidence of adverse events

adrenotropic hormone levels

glycocated hemoglobin

height and body weight. (3) Economy

cost-effectiveness analysis and minimum cost analysis showed that FP was more economical than BUD with morning / night PEF

forced expiratory volume at one second (FEV1)

forced vital capacity (FVC)

daytime absence of asthma attack

daytime / night emergency reliever as the effect indicators. Taking the absence of asthma attack at night as effect indicator

BUD was more cost-effective than FP. When the willingness-to-pay ( WTP) was less than 160. 00 yuan

FP was more economical than BUD. ( 4) Suitability

compared with beclomethasone (BDP)

FP and BUD had more pharmacological advantages. FP was the child-specific medication of ICS for children over 4 years old. FP had the longest drug validity date

which could reduce the cost of drug management in primary medical institutions and was conducive to long-term treatment of disease management. Inhaled BUD was available in a variety of generic versions and could be used in children over 6 months old. Inhaled BDP suspension could be used in children over 2 years old. (5) Accessibility

the coverage rate of medical institutions was BUD > BDP > FP ( original). Most generic BUD had higher coverage rate of medical institutions due to the entry into the collection catalog in China. From the perspective of affordability

the treatment course cost was FP